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Initiation of a protective immune response to infection by the pathogenic fungus Cryptococcus neoformans is mediated in part
by host factors that promote interactions between immune cells and C. neoformans yeast. Surfactant protein A (SP-A)
contributes positively to pulmonary host defenses against a variety of bacteria, viruses, and fungi in part by promoting the
recognition and phagocytosis of these pathogens by alveolar macrophages. In the present study we investigated the role of
SP-A as a mediator of host defense against the pulmonary pathogen, C. neoformans. Previous studies have shown that SP-A
binds to acapsular and minimally encapsulated strains of C. neoformans. Using in vitro binding assays we confirmed that SP-A
does not directly bind to a fully encapsulated strain of C. neoformans (H99). However, we observed that when C. neoformans
was incubated in bronchoalveolar fluid, SP-A binding was detected, suggesting that another alveolar host factor may enable
SP-A binding. Indeed, we discovered that SP-A binds encapsulated C. neoformans via a previously unknown IgG dependent
mechanism. The consequence of this interaction was the inhibition of IgG-mediated phagocytosis of C. neoformans by alveolar
macrophages. Therefore, to assess the contribution of SP-A to the pulmonary host defenses we compared in vivo infections
using SP-A null mice (SP-A-/-) and wild-type mice in an intranasal infection model. We found that the immune response
assessed by cellular counts, TNFa cytokine production, and fungal burden in lungs and bronchoalveolar lavage fluids during
early stages of infection were equivalent. Furthermore, the survival outcome of C. neoformans infection was equivalent in SP-
A-/- and wild-type mice. Our results suggest that unlike a variety of bacteria, viruses, and other fungi, progression of disease
with an inhalational challenge of C. neoformans does not appear to be negatively or positively affected by SP-A mediated
mechanisms of pulmonary host defense.
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INTRODUCTION
Cryptococcus neoformans is an environmentally ubiquitous fungal
pathogen that is responsible for significant morbidity and mortality
in immunocompromised hosts. In humans, a pulmonary infection
occurs following inhalation of C. neoformans cells. The identity of
the infectious propagule remains unknown but is presumed to be
either small, poorly encapsulated, desiccated yeasts or basidio-
spores. Hematogenous dissemination of C. neoformans from the
lungs to the central nervous system can result in cryptococcal
meningoencephalitis, a life-threatening complication that requires
aggressive chemotherapeutic intervention [1]. In healthy hosts,
initiation of an innate and adaptive cellular immune response
limits the severity of the infection to an asymptomatic and often
self-resolving pulmonary infection in most cases. The identification
of those host factors that contribute to effective defenses against C.
neoformans will not only broaden our understanding of C. neoformans
pathogenesis but may aide in the development of therapeutic
strategies for the prevention and treatment of this important fungal
disease.
Surfactant protein A (SP-A) is one such innate host factor that
has been shown to contribute positively to the pulmonary defenses
against a diverse group of pathogenic microorganisms including,
Pseudomonas aeruginosa [2], Streptococcus pneumoniae [2], Respiratory
Syncytial Virus [3], Influenza A virus [4], and the fungi Aspergillus
fumigatus [5] and Pneumocystis jiroveci [6]. SP-A mediates host defense
via direct interactions between the carbohydrate recognition
domain of SP-A and microbial ligands, which results in the
opsonization and phagocytosis of pathogenic microorganisms by
alveolar macrophages, and indirectly via modulation of the host
immune response [7–9]. Previous in vitro studies have shown that
SP-A can bind to acapsular and minimally encapsulated strains of
C. neoformans but not heavily-encapsulated yeast [10,11]. The role
of SP-A in host defenses against C. neoformans remains to be fully
elucidated.
In the present study we investigated the effect of SP-A on host
defense against an encapsulated, pathogenic strain of C. neoformans
(H99) [1]. The rationale for studying an encapsulated fully virulent
strain was two-fold. First, acapsular strains of C. neoformans are
uniformly avirulent, not clinically relevant and thus would not be
suitable for investigating the role of SP-A as a mediator of host
defense. Second, if a desiccated yeast form or basidiospore of C.
neoformans were inhaled, rapid rehydration of capsule occurs in
airway structures and the capsular structure is expected to be a
major factor in the initial host-pathogen pulmonary interaction.
We, therefore, initiated our study by first investigating the direct
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we confirmed that SP-A does not directly bind to C. neoformans but,
we did discover an IgG dependent mechanism that does enable
SP-A binding to C. neoformans. SP-A-/- mice and a murine
cryptococcosis inhalation infection model were then used to
investigate the role of SP-A in host defense against C. neoformans.
These experiments revealed that SP-A does not appear to
contribute to the pulmonary host defenses against C. neoformans.
MATERIALS AND METHODS
Strains and media
Cryptococcus neoformans var. grubii strains H99 (serotype A, mating
type alpha) was revived from 15% glycerol stocks stored at 280uC.
H99 was maintained on yeast extract peptone dextrose (YPD; 1%
yeast extract, 2% peptone and 2% dextrose) agar plates at 30uC.
Prior to use in these studies, yeast were grown in YPD liquid
medium overnight at 30uC, harvested, washed three times with
sterile phosphate-buffered saline (PBS), suspended in phagocytosis
buffer and counted with a hemacytometer to determine cell
concentrations. For phagocytosis assays, C. neoformans were labeled
with Alexa Fluor 647 (Invitrogen, Carlsbad, CA) per the
manufacturers instructions. Stocks of Alexa Fluor 647 labeled
yeast were maintained at 220uC until needed.
Purification and Alexa Fluor 488 labeling of
surfactant protein A
SP-A was isolated from the lavage fluid of alveolar proteinosis
patients as previously described [12]. Briefly, the surfactant pellet
from the lavage fluid was extracted with butanol. Butanol insoluble
proteins were then resuspended in octylglucopyranoside (OGP) in
0.15 M NaCl. SP-A, which is insoluble in OGP and salt, was then
suspended in Tris-buffered water, pH 7.4. Remaining OGP was
removed by dialysis against 5 mM Tris-buffered water, pH 7.4.
SP-A was then treated with polymyxin agarose beads to remove
endotoxin as previously described [12]. All SP-A preparations
were assayed for endotoxin contamination using the Limulus
amebocyte lysate assay (BioWhittaker, Rockland, ME) per the
manufacturer’s instructions. SP-A was labeled with Alexa Fluor
488 (Invitrogen, Carlsbad, CA) per the manufactures instructions.
The ratio of moles dye per mole of protein was quantified and SP-
A preparations with labeling efficiencies between 4 and 10 were
used for binding assays.
Surfactant protein A binding assays
To assess SP-A binding to C. neoformans, yeast were treated with
Alexa Fluor 488 labeled SP-A (5 to 20 mg/ml), anti-GXM IgG
mAb 18B7 (1.0 mg/ml, generous gift of Arturo Casadevall) or a
combination of SP-A and anti-GXM IgG for 60 minutes at 37uC
with shaking. Following treatment, yeast were washed twice with 5
volumes of phagocytosis buffer (PB) (PBS +0.1% BSA +900 mM
CaCl2) and binding was quantified by flow cytometric analysis
(Duke University Human Vaccine Institute Flow Cytometry Core
Facility, Durham, NC). Data analysis was performed using the
FlowJo software package (Ver. 6.3.3, Tree Star, Inc., Ashland,
OR). For fluorescence microscopy experiments, PE-Texas Red
(Invitrogen, Carlsbad, CA) labeled anti-GXM IgG mAb 18B7 was
used to detect C. neoformans capsule. Calcofluor was used to stain
the cell wall. SP-A binding assays using Escherichia coli HB101 were
used to validate the binding activity of all SP-A preparations used
in this study. Binding was visualized by fluorescent microscopy
(Zeiss Axioskop 2 Plus microscope). Fluorescent images were
captured using an AxioCam MRm (Carl Zeiss, Thornwood, NY)
digital camera and AxioVision 4.5 software (Carl Zeiss, Thorn-
wood, NY). Images were uniformly processed to adjust contrast
and image clarity using Adobe Photoshop CS2.
Uptake and binding assays
Alveolar macrophages were isolated from Sprague-Dawley rats
(Taconic, Germantown, NY). Bronchoalveolar lavage (BAL) was
performed with 10 ml of PBS containing 0.2 mM EGTA
(instilled 10 times). Cells were washed once with PBS and
resuspended in PB. Prior to the addition of Alexa Fluor 647
labeled C. neoformans to alveolar macrophages, yeast were
incubated with SP-A (5 to 20 mg/ml), anti-GXM IgG (1.0 mg/
ml) or a combination of SP-A and anti-GXM IgG at 37uC for
60 minutes with shaking. Yeast were washed twice with 5
volumes of PB and added to alveolar macrophages in suspension
at a multiplicity of infection of 1:1. Yeast and alveolar
macrophages were co-incubated for 60 minutes at 37uC with
Figure 1. SP-A does not directly bind to encapsulated C. neoformans yeast. (A.) C. neoformans (1610
5) were treated with Alexa Flour 488 labeled
SP-A (20 mg/ml) for 60 minutes at 37uC. Surfactant protein binding was quantified by flow cytometric analysis. SP-A binding was not detected. (B.) In
contrast, C. neoformans (1610
5) treated with undiluted BAL exhibited a small amount of SP-A binding. Results are one representative experiment of
at least three (A.) or two (B.) experiments performed.
doi:10.1371/journal.pone.0001370.g001
C. neoformans and SP-A
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flow cytometric analysis.
In vivo testing
C. neoformans wild-type strain H99 was used to assess the immune
response and susceptibility of SP-A-/- mice to infection by C.
neoformans. The immune response to infection by C. neoformans was
assessed by infecting groups consisting of 5 or 10 SP-A-/- or wild-
type C57BL/6 mice via intranasal inhalation with 1610
4 or
1610
5 CFU of each strain (in a volume of 50 ml), as described
previously [13]. The rationale for using 1610
4 yeast for studies
that assessed the host immune response was so that we could
measure the immune response to a relatively small number of C.
Figure 2. SP-A can bind C. neoformans via an IgG dependent mechanism. (A.) C. neoformans yeast (1610
5) were treated with AF488 labeled SP-A
(Panel A), PE-Texas Red labeled anti-GXM IgG (Panel B) and PE-Texas Red labeled anti-GXM IgG and AF488 labeled SP-A (Panel C). Calcofluor was
added to all samples to visualize the cell wall. SP-A binding to IgG opsonized (Panel C) but not non-opsonized (Panel A) C. neoformans was observed.
Scale bar length is equal to 10 mm. (B.) IgG opsonized C. neoformans were treated with SP-A concentrations of 1, 10, 20, 40 mg/ml and binding was
quantified by flow cytometric analysis. EDTA (1 mM) was included to determine if SP-A binding required the carbohydrate recognition domain.
Histograms represent the mean fluorescence intensity of the AF 488 channel. At least 10,000 particles were interrogated for each sample.
doi:10.1371/journal.pone.0001370.g002
C. neoformans and SP-A
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inoculum of 1610
5 yeast, which is a common inoculum size used
for susceptibility studies. Bronchoalveolar lavages (1 ml sterile PBS
instilled times 3; recovery 0.8–0.9 ml) were performed and total
lung tissues were collected for colony forming unit determination
at days three and seven post-infection. These time points were
chosen so as to capture early events in the immune response to C.
neoformans. Mouse TNFa ELISAs (R&D Systems) were performed
on bronchoalveolar lavage fluid per the manufacture’s instruction.
Cell differentials were performed by microscopic examination of
cytospin preparations of BAL from mice seven days post infection.
Slides were prepared with Wright-Giemsa stain per the manufac-
turers instructions. Susceptibility studies were performed with
groups consisting of 5 SP-A-/- or wild-type C57BL/6 mice that
were infected via intranasal inhalation with 1610
5 CFU of each
strain (in a volume of 50 ml), as described previously [13–15]. Mice
that appeared moribund (i.e. lethargic or exhibiting rapid weight
loss) or in pain were euthanized. Mice were monitored twice daily
and the mean time to mortality between the groups was
determined. The Duke University Institutional Animal Use and
Care Committee approved the animal protocol used for these
experiments.
Statistics
Statistical analysis was performed using the JMP statistics package
(SAS, Cary, NC). Student’s T-test or ANOVA was used to assess
binding, phagocytosis and cell differential data for statistical
significance. Survival statistics were performed to evaluate mouse
survival data for statistical significance. P-values,0.05 were
considered statistically significant.
RESULTS
Antibody dependent SP-A binding to C. neoformans
Previous studies by Walenkamp et al. and Schelenz et al. showed
that in vitro, SP-A binding is restricted to acapsular and minimally
encapsulated strains of C. neoformans [10,11]. To confirm these
results, we performed flow cytometry to quantify AF488 labeled
SP-A binding to encapsulated C. neoformans yeast (1610
5). SP-A
binding assays using Escherichia coli HB101 were performed to
confirm the binding activity of all SP-A preparations (results not
shown). Our results were consistent with those of previous studies;
we did not observe SP-A binding to encapsulated H99 C.
neoformans yeasts (Figure 1A). To extend this observation to
biological fluids, C. neoformans yeasts (1610
5) were next treated with
undiluted bronchoalveolar lavage fluid (BAL). In contrast to the
previous conditions, we were able to detect a small amount of SP-
A binding under these conditions (Figure 1B). Our interpretation
of these results was that another factor present in BAL may have
enabled SP-A to bind to C. neoformans. In the process of considering
factors in BAL that might mediate SP-A binding to C. neoformans,
immunoglobulins were selected as candidates for binding assays.
Several studies have reported that naturally occurring IgG
antibodies can non-specifically bind to pathogenic fungi. In
addition, antibody binding can alter the physical properties of
the C. neoformans capsule and affect the ability of other opsonins,
such as complement to bind [16]. Therefore, we investigated
whether IgG antibody binding to capsule enabled SP-A binding to
C. neoformans. C. neoformans cells were opsonized with anti-GXM
IgG and then treated with AF488 labeled SP-A (20 mg/ml) or left
untreated as a control. Calcofluor was used to visualize the cell
wall. While SP-A did not bind directly to C. neoformans cells
(Figure 2A), the addition of anti-GXM IgG to the interaction
resulted in robust SP-A binding that appeared to co-localize with
anti-GXM IgG binding and was generally uniform throughout the
capsular matrix (Figure 2A). Due to the size of the capsule, some
areas bound by SP-A and anti-GXM IgG appear larger than the
yeast. Further analysis by flow cytometry demonstrated that SP-A
binding (1, 10, 20, and 40 mg/ml) to anti-GXM IgG opsonized C.
neoformans cells occurred in a dose-dependent manner (Figure 2B).
The carbohydrate recognition domain of SP-A is known to bind
sugars in a calcium dependent manner. We observed that EDTA
(1 mM) did not affect SP-A binding to anti-GXM IgG opsonized
C. neoformans, suggesting that the carbohydrate recognition domain
was not involved in this mechanism (Figure 2B). Furthermore, this
result suggested that SP-A binding to anti-GXM IgG opsonized C.
neoformans is not due to antibody mediated exposure of carbohy-
drate ligands.
SP-A inhibits IgG dependent phagocytosis of C.
neoformans by alveolar macrophages
We next investigated whether SP-A binding could functionally
affect IgG-mediated phagocytosis of C. neoformans by alveolar
macrophages in vitro. For these experiments C. neoformans cells
were fluorescently labeled with AF-647, which had no affect on
C. neoformans uptake by alveolar macrophages in preliminary
experiments (results not shown). Attachment/phagocytosis was
quantified by flow cytometry. Non-IgG opsonized C. neoformans
were attached/phagocytosed by less than 1% of the alveolar
macrophage population in the presence or absence of SP-A, thus
percent inhibition of uptake for these conditions is presented as
,100% (Figure 3). We observed that all the SP-A concentrations
tested (20, 40 and 80 mg/ml) significantly (P,0.001) inhibited the
uptake of anti-GXM IgG opsonized C. neoformans yeast by
alveolar macrophages and that this inhibition occurred in a
dose dependent manner (1663.1%, 3462.7% and 4663.0%,
Figure 3. SP-A inhibits the uptake of IgG opsonized C. neoformans by
alveolar macrophages. Non-IgG opsonized C. neoformans were
attached/phagocytosed by less than 1% of the alveolar macrophage
population in the presence or absence of SP-A, thus percent inhibition
of uptake for these conditions is presented as ,100%. SP-A (20, 40 and
80 mg/ml) significantly (P,0.001) inhibited the uptake of IgG opsonized
C. neoformans (1610
5) by alveolar macrophages (1610
5) in a dose
dependent manner (1663.1%, 3462.7% and 4663.0%, respectively).
Results represent the mean plus or minus the standard error of the
mean of three experiments.
doi:10.1371/journal.pone.0001370.g003
C. neoformans and SP-A
PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1370Figure 4. C. neoformans infection appears to progress equivalently in SP-A-/- and wild-type mice. (A.) Three days post infection the fungal
burdens of lung tissue and BALs from wild-type (n=4 and n=7, respectively) and SP-A-/- (n=3 and n=8, respectively) mice were equivalent. (B.) A
similar trend was observed at day seven post infection; no difference between groups were observed. (C.) Quantitative differentials showed no
differences in the numbers of macrophages, polymorphonuclear neutrophils or lymphocytes present in BALs collected from wild-type (n=3) and SP-
A-/- (n=3) mice seven days post infection. (D.) There were also no differences in the numbers of macrophages from SP-A-/- (n=3) and wild-type mice
(n=3) that had phagocytosed C. neoformans. TNFa levels (measured by ELISA) in the lungs of wild-type and SP-A-/- mice at day three (n=8 and n=7,
respectively) and seven (n=16 and n=17, respectively) post infection were equivalent (P.0.05). Results represent the mean plus or minus the
standard error of the mean for the indicated number of experiments. (AM, alveolar macrophage; PMN, polymorphonuclear neutrophils; Lymphs,
lymphocytes; BAL, bronchoalveolar fluid)
doi:10.1371/journal.pone.0001370.g004
C. neoformans and SP-A
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mechanism by which SP-A inhibits, rather than enhances, the
phagocytosis of an antibody opsonized microorganism by
alveolar macrophages.
SP-A-/- mice exhibit wild-type susceptibility to C.
neoformans
Our in vitro studies suggested that the classic role of SP-A as an
opsonin was unlikely to contribute to host defense against C.
neoformans. In fact, its affect on IgG-mediated phagocytosis could
enhance extracellular colonization and thus change the growth
and dissemination of C. neoformans in vivo. Furthermore, SP-A is
also known to contribute to host defense via other mechanisms,
such as modulation of the immune response. Therefore, we
could not predict the impact of SP-A on cryptococcosis. We
explored the role of SP-A as a modulator of the early immune
response against C. neoformans using a murine pulmonary
infection model and an SP-A deficient mouse strain (SP-A-/-).
Groups of SP-A-/- and wild-type mice were infected via
intranasal inoculation with C. neoformans cells (1610
4) and several
defined endpoints were analyzed at days three and seven post
infection.
We began by first investigating whether SP-A deficiency
affected the colonization of the lungs by C. neoformans.
Bronchoalveolar lavage fluid and lung tissue were collected from
SP-A-/- (n=3 and n=8, respectively) and wild-type (n=4 and
n=7, respectively) mice at days three and seven post infection.
We found that SP-A deficiency did not affect the colonization of
the lungs by C. neoformans (Figure 4A). At day seven post infection
a significantly greater (P,0.001) number of yeast were present
in the lung tissue of both mouse strains, as compared to the
bronchoalveolar lavage fluid (Figure 4B), suggesting that C.
neoformans had equally invaded the pulmonary parenchyma of
both strains.
We then investigated whether SP-A deficiency affected the
recruitment of immune cells to the lungs in response to this
infection in both murine strains. We found that the numbers of
alveolar macrophages, polymorphonuclear cells or lymphocytes in
the bronchoalveolar lavage fluid of SP-A-/- (n=3) and wild-type
(n=3) mice at day seven day post infection were equivalent
(Figure 4C), suggesting that SP-A deficiency did not affect the
recruitment of immune cells in response to infection by C.
neoformans. Furthermore, no significant (P.0.05) differences
between the numbers of C. neoformans cells phagocytosed by
alveolar macrophages from SP-A-/- (n=3), as compared to wild-
type (n=3) mice was observed (Figure 4D). To investigate the
impact on cytokine response to infection by C. neoformans,w e
measured a major Th1 cytokine, TNFa. We found that TNFa
levels in bronchoalveolar lavage fluid from SP-A-/- and wild-type
mice did not differ significantly at day three (n=8 and n=7,
respectively) and seven (n=16 and n=17, respectively) post
infection (Figure 4E and 4F). These results support the concept
that SP-A deficiency did not affect TNFa production in response
to infection by C. neoformans.
As a final comparison of SP-A impact on infection, groups of 5
SP-A-/- and wild-type mice were infected by intranasal inoculation
with C. neoformans yeast (1610
5) to investigate whether SP-A
deficiency affected the final outcome of infection. By day 32 of
infection all mice had succumbed to infection and died with no
significant difference (P.0.05) in the mean time of mortality
between the two groups (Figure 5). These results support the
concept that SP-A deficiency does not affect the susceptibility of
mice to infection by C. neoformans.
DISCUSSION
The inability of SP-A to bind encapsulated strains of C. neoformans
is surprising given that SP-A binds a diverse assortment of
carbohydrates and that the C. neoformans capsule and cell wall
possess abundant and varied carbohydrates. Indeed, SP-A binds
well to other pathogenic fungi including Aspergillus fumigatus [5],
Pneumocystis jiroveci [17], Coccidioides posadasii [18], and Histoplasma
capsulatum [19]. One explanation of these results may be found in
studies that investigated SP-A binding to the yeast Saccharomyces
cerevisiae. These studies found that despite the presence of accessible
carbohydrates on the cell surface of S. cerevisiae SP-A does not bind
to this yeast [20,21]. This was hypothesized to be due to charge
repulsion; SP-A and S. cerevisiae cell wall mannan both carry a net
negative charge at pH 7.4 [21]. The capsular polysaccharide that
surrounds C. neoformans yeast, which can reach diameters as large
as 80 mm [22,23] is very highly negatively charged [24]. It is
possible that the absence of SP-A binding to C. neoformans is also
due to charge repulsion. Since the concentrations of SP-A used in
our in vitro binding assays were comparable or even higher than
those thought to exist in the lungs of healthy individuals under
physiological conditions (1 to 2 mg/ml) [11], it is unlikely that the
binding deficiency was simply due to limited availability of SP-A.
This is the first report that has demonstrated IgG dependent
binding of SP-A to a microorganism. Several lines of evidence
suggest that this occurs via a mechanism in which IgG first binds
to C. neoformans capsule and then SP-A binds to bound IgG. First,
we showed that SP-A binding was not inhibited by EDTA,
demonstrating that the SP-A carbohydrate recognition domain
was not required. This ruled out the possibility of SP-A binding to
carbohydrate ligands that may have been exposed as a result of
anti-GXM IgG binding. Second, SP-A binding inhibited the
IgG dependent phagocytosis of C. neoformans yeast by alveolar
macrophages. This observation suggested that SP-A binding
functionally interfered with IgG binging to the Fcc receptor on
the cell surface of alveolar macrophages, which is required for
phagocytosis in the case of C. neoformans [1]. Third, a recent study
in our laboratory showed that SP-A can bind directly to the Fc
Figure 5. SP-A deficiency does not enhance susceptibility to infection
by C. neoformans. Groups of 5 SP-A-/- and wild-type mice were
infected with C. neoformans (H99, 1610
5) via intranasal inhalation. All
mice succumbed to infection and died by day 32. There was no
difference in the mean time to death of SP-A-/- and wild-type C57BL/6
mice.
doi:10.1371/journal.pone.0001370.g005
C. neoformans and SP-A
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relevant concentrations for these studies, our results suggest that
this interaction could occur under in vivo conditions.
SP-A mediated mechanisms of host defense provide protection
against several pathogenic fungi. For example, SP-A enhances the
phagocytosis and killing of Aspergillus fumigatus conidia by alveolar
macrophages and neutrophils [5]. In addition, administration of
SP-A to mice with invasive aspergillosis rescued them from death
[26]. Studies with SP-A-/- mice have shown that SP-A deficiency
results in increased susceptibility to infection by P. jiroveci [27] and
H. capsulatum [19]. However, this is not the case for C. neoformans.
The end points analyzed in our in vivo studies clearly demonstrated
an equivalent progression and outcome of disease in SP-A-/- and
wild-type mice.
Another mechanism by which SP-A can mediate host defense is
via direct modulation of alveolar macrophage function. SP-A can
reduce reactive oxygen intermediate production by alveolar
macrophages via the down regulation of NADPH oxidase [28].
Thus, alveolar macrophages in SP-A-/- mice would be expected
to produce increased levels of reactive oxygen species as
compared to wild-type mice. This up regulation of reactive
oxygen species however would not be expected to have a
significant effect on C. neoformans colonization of the lungs since C.
neoformans possesses a highly robust antioxidant defense system
[13–15] and the absence or presence of SP-A had no impact on
yeast growth, host immune cell recruitment or cytokine
production. Taken together, the in vitro and in vivo results of this
study suggest that unlike a variety of bacteria, viruses and other
fungi, the encapsulated yeast C. neoformans does not appear to be
susceptible to SP-A mediated mechanisms of innate immunity in
the murine pulmonary tract.
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